Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion Inc (BMEA)
:BMEA
BMEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.27 - $16.29
Previous CloseN/A
Volume309.16K
Average Volume (3M)620.90K
Market Cap
$83.35M
Enterprise Value$287.44M
Total Cash (Recent Filing)-$239.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Apr 30, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding36,238,686
10 Day Avg. Volume668,720
30 Day Avg. Volume620,896
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.42
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
$21.40Price Target Upside830.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Biomea Fusion News
PremiumCompany Announcements
Biomea Fusion Appoints Interim CEO Amid Leadership Changes---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBiomea announced positive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D.
Drug EfficacyIcovamenib exhibited a significant mean HbA1c reduction of 1.47% and a 53% increase in C-peptide after 14 weeks off-therapy in severe insulin-deficient diabetes patients, with no safety concerns.
Bears Say
Clinical DevelopmentExperts look forward to upcoming later-stage clinical development steps for icovamenib, highlighting its potential for combinations with GLP-1 receptor agonists and as an adjuvant for type 1 diabetes.
Treatment DurationIcovamenib's proposed mechanism of action leads to a persistent increase in C-peptide levels, suggesting restoration of endogenous insulin production and enhanced β-cell function.
---
Ownership Overview
17.81% Insiders
14.89% Mutual Funds
21.50% Other Institutional Investors
37.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion Inc’s price range in the past 12 months?
Biomea Fusion Inc lowest stock price was $2.27 and its highest was $16.29 in the past 12 months.
What is Biomea Fusion Inc’s market cap?
Biomea Fusion Inc’s market cap is $83.35M.
When is Biomea Fusion Inc’s upcoming earnings report date?
Biomea Fusion Inc’s upcoming earnings report date is Apr 30, 2025 which is in 29 days.
How were Biomea Fusion Inc’s earnings last quarter?
Biomea Fusion Inc released its earnings results on Mar 03, 2025. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.912 by $0.102.
Is Biomea Fusion Inc overvalued?
According to Wall Street analysts Biomea Fusion Inc’s price is currently Undervalued.
Does Biomea Fusion Inc pay dividends?
Biomea Fusion Inc does not currently pay dividends.
What is Biomea Fusion Inc’s EPS estimate?
Biomea Fusion Inc’s EPS estimate is -0.92.
How many shares outstanding does Biomea Fusion Inc have?
Biomea Fusion Inc has 36,238,686 shares outstanding.
What happened to Biomea Fusion Inc’s price movement after its last earnings report?
Biomea Fusion Inc reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.912. Following the earnings report the stock price went down -8.651%.
Which hedge fund is a major shareholder of Biomea Fusion Inc?
Currently, no hedge funds are holding shares in BMEA
---
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (830.43% Upside)
$21.40 (830.43% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 575.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.75%
12-Months-Change
Fundamentals
Return on Equity
-104.51%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Biomea Fusion Inc
Biomea Fusion (BMEA) is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. The company leverages its proprietary FUSION™ System to design and develop next-generation covalent small molecules that target key drivers of disease.
---
BMEA Stock 12 Month Forecast
Average Price Target
$21.40
▲(830.43% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-9.08%
reiterated a buy rating 5 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -9.08% per trade.
---